{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:40:15Z","timestamp":1788316815252,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10067-026-08212-w","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T03:35:54Z","timestamp":1781148954000},"page":"4159-4173","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["GLP-1\u2013based therapy and ICD-10\u2013documented heart failure or respiratory failure events in non-diabetic adults with rheumatoid arthritis and obesity: a TriNetX federated cohort study"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4113-2221","authenticated-orcid":false,"given":"Giorgos","family":"Loizidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4615-4956","authenticated-orcid":false,"given":"Ross","family":"Summer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"8212_CR1","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/art.24092","volume":"59","author":"JA Avi\u00f1a-Zubieta","year":"2008","unstructured":"Avi\u00f1a-Zubieta JA, Choi HK, Sadatsafavi Mea et al (2008) Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 59:1690\u20131697. https:\/\/doi.org\/10.1002\/art.24092","journal-title":"Arthritis Rheum"},{"key":"8212_CR2","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/art.20855","volume":"52","author":"PJ Nicola","year":"2005","unstructured":"Nicola PJ, Maradit-Kremers H, Roger Vea, Roger VL et al (2005) The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 52:412\u2013420. https:\/\/doi.org\/10.1002\/art.20855","journal-title":"Arthritis Rheum"},{"key":"8212_CR3","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1002\/art.21349","volume":"52","author":"CS Crowson","year":"2005","unstructured":"Crowson CS, Nicola PJ, Kremers Hea, Kremers HM et al (2005) How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? Arthritis Rheum 52:3039\u20133044. https:\/\/doi.org\/10.1002\/art.21349","journal-title":"Arthritis Rheum"},{"key":"8212_CR4","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/acr.25481","volume":"77","author":"Y Kawano","year":"2025","unstructured":"Kawano Y, Weber BN, Weisenfeld Dea et al (2025) Risk of incident heart failure and heart failure subtypes in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 77:631\u2013639. https:\/\/doi.org\/10.1002\/acr.25481","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8212_CR5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/art.41979","volume":"74","author":"E Park","year":"2022","unstructured":"Park E, Griffin J, Bathon JM (2022) Myocardial dysfunction and heart failure in rheumatoid arthritis. Arthritis Rheumatol 74:184\u2013199. https:\/\/doi.org\/10.1002\/art.41979","journal-title":"Arthritis Rheumatol"},{"key":"8212_CR6","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.jacc.2016.12.033","volume":"69","author":"\u00c4 Mantel","year":"2017","unstructured":"Mantel \u00c4, Holmqvist M, Andersson Dea, Andersson DC et al (2017) Association between rheumatoid arthritis and risk of ischemic and nonischemic heart failure. J Am Coll Cardiol 69:1275\u20131285. https:\/\/doi.org\/10.1016\/j.jacc.2016.12.033","journal-title":"J Am Coll Cardiol"},{"key":"8212_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejim.2020.11.002","volume":"85","author":"MB Ferreira","year":"2021","unstructured":"Ferreira MB, Fonseca T, Costa R, Ferreira Jea et al (2021) Prevalence, risk factors and proteomic bioprofiles associated with heart failure in rheumatoid arthritis: the RA-HF study. Eur J Intern Med 85:41\u201349. https:\/\/doi.org\/10.1016\/j.ejim.2020.11.002","journal-title":"Eur J Intern Med"},{"key":"8212_CR8","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.cardfail.2021.01.018","volume":"27","author":"PE Miller","year":"2021","unstructured":"Miller PE, Van Diepen S, Metkus Tea et al (2021) Association between respiratory failure and clinical outcomes in patients with acute heart failure: analysis of 5 pooled clinical trials. J Card Fail 27:602\u2013606. https:\/\/doi.org\/10.1016\/j.cardfail.2021.01.018","journal-title":"J Card Fail"},{"issue":"10","key":"8212_CR9","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/art.24109","volume":"59","author":"JT Giles","year":"2008","unstructured":"Giles JT, Bartlett SJ, Andersen Rea et al (2008) Association of body composition with disability in rheumatoid arthritis: impact of appendicular fat and lean tissue mass. Arthritis Rheum 59(10):1407\u20131415. https:\/\/doi.org\/10.1002\/art.24109","journal-title":"Arthritis Rheum"},{"key":"8212_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.855141","volume":"9","author":"W Cai","year":"2022","unstructured":"Cai W, Tang X, Pang M (2022) Prevalence of metabolic syndrome in patients with rheumatoid arthritis: an updated systematic review and meta-analysis. Front Med (Lausanne) 9:855141. https:\/\/doi.org\/10.3389\/fmed.2022.855141","journal-title":"Front Med (Lausanne)"},{"key":"8212_CR11","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1093\/rheumatology\/keac307","volume":"62","author":"VK Ranganath","year":"2023","unstructured":"Ranganath VK, La Cava A, Vangala Sea et al (2023) Improved outcomes in rheumatoid arthritis with obesity after a weight loss intervention: randomized trial. Rheumatology (Oxford) 62:565\u2013574. https:\/\/doi.org\/10.1093\/rheumatology\/keac307","journal-title":"Rheumatology (Oxford)"},{"key":"8212_CR12","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1002\/acr.25117","volume":"75","author":"BR England","year":"2023","unstructured":"England BR, Smith BJ, Baker NA et al (2023) 2022 American College of Rheumatology guideline for exercise, rehabilitation, diet, and additional integrative interventions for rheumatoid arthritis. Arthritis Care Res (Hoboken) 75:1603\u20131615. https:\/\/doi.org\/10.1002\/acr.25117","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8212_CR13","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun Hea et al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 389:2221\u20132232. https:\/\/doi.org\/10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"8212_CR14","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug Bea et al (2023) Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 389:1069\u20131084. https:\/\/doi.org\/10.1056\/NEJMoa2306963","journal-title":"N Engl J Med"},{"key":"8212_CR15","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug Bea et al (2024) Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med 390:1394\u20131407. https:\/\/doi.org\/10.1056\/NEJMoa2313917","journal-title":"N Engl J Med"},{"key":"8212_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer Cea, Kramer CM et al (2025) Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 392:427\u2013437. https:\/\/doi.org\/10.1056\/NEJMoa2410027","journal-title":"N Engl J Med"},{"key":"8212_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P et al (2024) Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 391:109\u2013121. https:\/\/doi.org\/10.1056\/NEJMoa2403347","journal-title":"N Engl J Med"},{"issue":"25","key":"8212_CR18","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","volume":"6736","author":"J Deanfield","year":"2025","unstructured":"Deanfield J, Lincoff AM, Kahn SE et al (2025) Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet 6736(25):2257\u20132268. https:\/\/doi.org\/10.1016\/S0140-6736(25)01375-3","journal-title":"Lancet"},{"issue":"1","key":"8212_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13098-023-01118-6","volume":"15","author":"M Yu","year":"2023","unstructured":"Yu M, Wang R, Pei Lea, Wang J, Wang L et al (2023) The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials. Diabetol Metab Syndr 15:164, 164. https:\/\/doi.org\/10.1186\/s13098-023-01118-6","journal-title":"Diabetol Metab Syndr"},{"key":"8212_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0308533","volume":"19","author":"D Karacabeyli","year":"2024","unstructured":"Karacabeyli D, Lacaille D, Lu Nea et al (2024) Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: a population-based study. PLoS One 19:e0308533. https:\/\/doi.org\/10.1371\/journal.pone.0308533","journal-title":"PLoS One"},{"key":"8212_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70103","volume":"7","author":"DA Kellner","year":"2025","unstructured":"Kellner DA, Dente E, Tran V et al (2025) Effect of glucagon-like peptide 1 receptor agonists on patients with rheumatoid arthritis. ACR Open Rheumatol 7:e70103. https:\/\/doi.org\/10.1002\/acr2.70103","journal-title":"ACR Open Rheumatol"},{"key":"8212_CR22","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/pds.4297","volume":"26","author":"ML Berger","year":"2017","unstructured":"Berger ML, Sox H, Willke Rea et al (2017) Good practices for real-world data studies of treatment and\/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf 26:1033\u20131039. https:\/\/doi.org\/10.1002\/pds.4297","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"8212_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076460","volume":"384","author":"RJ Desai","year":"2024","unstructured":"Desai RJ, Wang SV, Sreedhara Sea et al (2024) Process guide for inferential studies using healthcare data from routine clinical practice to evaluate causal effects of drugs (PRINCIPLED): considerations from the FDA Sentinel Innovation Center. BMJ 384:e076460. https:\/\/doi.org\/10.1136\/bmj-2023-076460","journal-title":"BMJ"},{"key":"8212_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/jamiaopen\/ooad035","volume":"6","author":"MB Palchuk","year":"2023","unstructured":"Palchuk MB, London JW, Perez-Rey Dea et al (2023) A global federated real-world data and analytics platform for research. JAMIA Open 6:ooad035. https:\/\/doi.org\/10.1093\/jamiaopen\/ooad035","journal-title":"JAMIA Open"},{"key":"8212_CR25","doi-asserted-by":"publisher","first-page":"1516126","DOI":"10.3389\/fphar.2025.1516126","volume":"16","author":"RJ Ludwig","year":"2025","unstructured":"Ludwig RJ, Anson M, Zirpel Hea et al (2025) A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX. Front Pharmacol 16:1516126, 1516126. https:\/\/doi.org\/10.3389\/fphar.2025.1516126","journal-title":"Front Pharmacol"},{"issue":"2","key":"8212_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.71079\/aside.im.03222516","volume":"1","author":"M Nassar","year":"2025","unstructured":"Nassar M, Abosheaishaa H, Elfert Kea et al (2025) TriNetX and real-world evidence: a critical review of its strengths, limitations, and bias considerations in clinical research. ASIDE Intern Med 1(2):24\u201333. https:\/\/doi.org\/10.71079\/aside.im.03222516","journal-title":"ASIDE Intern Med"},{"key":"8212_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-025-01342-6","author":"YJ Lin","year":"2026","unstructured":"Lin YJ, Tsai KW, Lu KC, Wang J (2026) On the reported methodology in published TriNetX-based studies: an analysis of impossible index event designs. Eur J Epidemiol. https:\/\/doi.org\/10.1007\/s10654-025-01342-6","journal-title":"Eur J Epidemiol"},{"issue":"07","key":"8212_CR28","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"6736","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger Mea et al (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 6736(07):1453\u20131457. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X","journal-title":"Lancet"},{"key":"8212_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885","volume":"12","author":"EI Benchimol","year":"2015","unstructured":"Benchimol EI, Smeeth L, Guttmann Aea et al (2015) The Reporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med 12:e1001885. https:\/\/doi.org\/10.1371\/journal.pmed.1001885","journal-title":"PLoS Med"},{"key":"8212_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3532","volume":"363","author":"SM Langan","year":"2018","unstructured":"Langan SM, Schmidt SAJ, Wing K, Schmidt SAJ et al (2018) The Reporting of studies Conducted using Observational Routinely collected health Data Statement for Pharmacoepidemiology (RECORD-PE). BMJ 363:k3532. https:\/\/doi.org\/10.1136\/bmj.k3532","journal-title":"BMJ"},{"key":"8212_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","volume":"2","author":"JL Lund","year":"2015","unstructured":"Lund JL, Richardson DB, St\u00fcrmer T (2015) The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep 2:221\u2013228. https:\/\/doi.org\/10.1007\/s40471-015-0053-5","journal-title":"Curr Epidemiol Rep"},{"key":"8212_CR32","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM (2016) Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol 183:758\u2013764. https:\/\/doi.org\/10.1093\/aje\/kwv254","journal-title":"Am J Epidemiol"},{"key":"8212_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/pds.5407","volume":"31","author":"R Sendor","year":"2022","unstructured":"Sendor R, St\u00fcrmer T (2022) Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators. Pharmacoepidemiol Drug Saf 31:261\u2013269. https:\/\/doi.org\/10.1002\/pds.5407","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Suppl 1","key":"8212_CR34","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/pds.2313","volume":"21","author":"JS Saczynski","year":"2012","unstructured":"Saczynski JS, Andrade SE, Harrold Lea, Harrold LR et al (2012) A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Saf 21(Suppl 1):129\u2013140. https:\/\/doi.org\/10.1002\/pds.2313","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"8212_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104519","volume":"9","author":"N McCormick","year":"2014","unstructured":"McCormick N, Lacaille D, Bhole V, Avi\u00f1a-Zubieta JA (2014) Validity of heart failure diagnoses in administrative databases: a systematic review and meta-analysis. PLoS One 9:e104519. https:\/\/doi.org\/10.1371\/journal.pone.0104519","journal-title":"PLoS One"},{"key":"8212_CR36","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000000128","volume":"2","author":"JA Kempker","year":"2020","unstructured":"Kempker JA, Abril MK, Chen Yea et al (2020) The epidemiology of respiratory failure in the United States 2002\u20132017: a serial cross-sectional study. Crit Care Explor 2:e0128. https:\/\/doi.org\/10.1097\/CCE.0000000000000128","journal-title":"Crit Care Explor"},{"key":"8212_CR37","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","volume":"21","author":"M Lipsitch","year":"2010","unstructured":"Lipsitch M, Tchetgen Tchetgen E, Cohen T (2010) Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology 21:383\u2013388. https:\/\/doi.org\/10.1097\/EDE.0b013e3181d61eeb","journal-title":"Epidemiology"},{"key":"8212_CR38","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46:399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786","journal-title":"Multivar Behav Res"},{"key":"8212_CR39","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P (2017) Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med 167:268\u2013274. https:\/\/doi.org\/10.7326\/M16-2607","journal-title":"Ann Intern Med"},{"key":"8212_CR40","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/acr.24444","volume":"74","author":"Z Izadi","year":"2022","unstructured":"Izadi Z, Schmajuk G, Gianfrancesco Mea et al (2022) Significant gains in rheumatoid arthritis quality measures among RISE registry practices. Arthritis Care Res (Hoboken) 74:219\u2013228. https:\/\/doi.org\/10.1002\/acr.24444","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"8212_CR41","doi-asserted-by":"publisher","first-page":"e2455222","DOI":"10.1001\/jamanetworkopen.2024.55222","volume":"8","author":"MI Podolsky","year":"2025","unstructured":"Podolsky MI, Raquib R, Shafer Pea et al (2025) Factors associated with semaglutide initiation among adults with obesity. JAMA Netw Open 8:e2455222. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.55222","journal-title":"JAMA Netw Open"},{"key":"8212_CR42","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1164\/rccm.202303-0491OC","volume":"208","author":"D Foer","year":"2023","unstructured":"Foer D, Strasser ZH, Cui Jea et al (2023) Association of GLP-1 receptor agonists with chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes. Am J Respir Crit Care Med 208:1088\u20131100. https:\/\/doi.org\/10.1164\/rccm.202303-0491OC","journal-title":"Am J Respir Crit Care Med"},{"key":"8212_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/art.70134","author":"JF Merola","year":"2026","unstructured":"Merola JF, Mease P, Kivitz A et al (2026) Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity: results from a randomized clinical trial (TOGETHER-PsA). Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.70134","journal-title":"Arthritis Rheumatol"},{"key":"8212_CR44","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.2147\/PPA.S277676","volume":"14","author":"T Weiss","year":"2020","unstructured":"Weiss T, Carr RD, Pal Sea et al (2020) Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes mellitus patients in the United States. Patient Prefer Adherence 14:2337\u20132345. https:\/\/doi.org\/10.2147\/PPA.S277676","journal-title":"Patient Prefer Adherence"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08212-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08212-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08212-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:28:16Z","timestamp":1783398496000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08212-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8212"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08212-w","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used de-identified data from the TriNetX US Collaborative Network. The Western Institutional Review Board granted TriNetX a waiver of informed consent under the HIPAA Privacy Rule (45 CFR \u00a7164.514). The study was exempt from additional institutional review board approval and was conducted in accordance with the principles of the Declaration of Helsinki (1964) and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was waived because all data were de-identified prior to analysis under the HIPAA Privacy Rule.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}